Logo

Biogen's Tysabri (natalizumab- SC) Receives EC's Marketing Authorization to Treat Relapsing-Remitting Multiple Sclerosis

Share this

Biogen's Tysabri (natalizumab- SC) Receives EC's Marketing Authorization to Treat Relapsing-Remitting Multiple Sclerosis

Shots:

  • The EC’s approval is based on data from DELIVER and REFINE studies evaluating the efficacy- PK- and PD of Tysabri (300mg- SC- q4w) vs Tysabri (300mg- IV- q4w) in patients with RRMS
  • The results demonstrated that the Tysabri (SC) in both studies showed clinical benefits and well-characterized safety profile. The SC option expands the clinical settings while safety is consistent with IV formulation in other clinical studies and the post-marketing setting
  • Tysabri is the only high-efficacy MS therapy to offer two routes of administration options thus- providing flexibility to meet patients' individual preferences and needs

  Ref: GlobeNewswire | Image: Biogen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions